Clorox Lifts Fiscal 2027 Outlook Following Q4 Beat and GOJO Acquisition

Clorox reported fiscal fourth-quarter results that surpassed analyst expectations, while raising its outlook for fiscal 2027, buoyed by momentum from its recently completed acquisition of GOJO Industries.

For the quarter ending June 30, Clorox posted adjusted earnings per share of $1.66, beating the consensus estimate of $1.65. Revenue came in at $1.95 billion, slightly above analysts’ expectations around $1.91–$1.92 billion, despite a 2% year-over-year decline in net sales. These results were accompanied by the completion of Clorox’s acquisition of GOJO Industries in April 2026, with the deal contributing notably to top-line performance. Organic sales, however, fell approximately 13%, mainly due to lapping incremental shipments associated with a prior-year ERP transition. GOJO added roughly 10 percentage points to Q4 net sales. According to Reuters, Clorox forecast net sales to grow between 13% and 14% in fiscal 2027, surpassing the analysts’ expectation of 12.8%. Adjusted EPS guidance for fiscal 2027 was set between $5.70 and $6.00, slightly above the $5.97 consensus estimate. The company also signaled durable demand in health and wellness segments and international markets, despite persistent macroeconomic headwinds and cost volatility.

Following the earnings release, analysts maintained a “Reduce” rating on the stock, with Clorox shares trading steady above $107.00. The company’s Q4 beat and upward FY2027 guidance appear to have stabilized investor sentiment for now, even though the rating suggests some cautiousness remains.

Implications for Clorox Investors

Clorox’s performance in Q4 underscores the accelerating importance of its GOJO acquisition in expanding health and hygiene sales. The 10-point contribution to net sales highlights the strategic value of the deal in offsetting declines in organic growth tied to disrupted supply and ERP transitions.

Looking ahead, fiscal 2027 guidance suggests the company expects to sustain improvement through both acquisition-driven growth and a gradual recovery in organic demand. While macroeconomic uncertainty and margin pressures persist, the added weight of GOJO and resilient categories may provide a buffer.

Key Metrics at a Glance

• Adjusted EPS for Q4: $1.66 (beat on $1.65) – Reuters
• Q4 Net Sales: $1.95B (down 2% YoY, beat ~ $1.91–$1.92B) – Reuters
• Organic sales: down ~13%; GOJO added ~10 percentage points to net sales – Reuters
• Fiscal 2027 Net Sales Guidance: +13% to +14% (vs 12.8% analyst estimate) – Reuters
• Fiscal 2027 Adjusted EPS Guidance: $5.70 to $6.00 (vs $5.97 consensus) – Reuters
• Stock reaction: shares held above $107; analysts reaffirmed “Reduce” rating – AD Hoc News

Investors should monitor how effectively Clorox integrates GOJO and restores organic growth, alongside managing cost pressures, as it progresses through fiscal 2027. Continued clarity around margin trajectory and consumer demand trends will be central to evaluating the outlook.